Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 4/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | KHK | P50053 | 2/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 4/20 | 0.34 |
| ▸ | TCF7L2 | Q9NQB0 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | USP28 | Q96RU2 | 4/20 | 0.33 |
| ▸ | USP25 | Q9UHP3 | 4/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008851 | 0.85 | SOS1 (0.50) | SOS1MPO | |
| SCHEMBL2003871 | 0.85 | CSNK1E (0.39) | PRKCICTNNB1TCF7L2 | |
| SCHEMBL1019878 | 0.84 | CNR1 (0.42) | KHKPRKCICTNNB1TCF7L2USP28 | |
| SCHEMBL2004219 | 0.84 | HTR6 (0.42) | KHK | |
| SCHEMBL2010491 | 0.83 | PRKCI (0.35) | SOS1MPOPRKCIDRD4TMEM97 | |
| SCHEMBL2012804 | 0.83 | CETP (0.44) | SOS1KHKPRKCIUSP25 | |
| SCHEMBL2005108 | 0.83 | HTR6 (0.41) | MPOKHKPIN1 | |
| SCHEMBL2007838 | 0.82 | SOS1 (0.47) | SOS1MPO | |
| SCHEMBL2006897 | 0.81 | KHK (0.41) | KHKSIGMAR1PIN1 | |
| SCHEMBL2005763 | 0.79 | HTR6 (0.40) | PRKCISIGMAR1USP28USP25PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960556-B2 | Thiadiazole derivatives for the treatment of neuro-degenerative diseases | NV REMYND (BE) | 2011-06-14 | — | — | US | disclosed |
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-06-10 | — | — | US | disclosed |
| EP-2094677-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV Remynd (BE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144709-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | SNCA, PARK7, PRNP | SOS1 4472/4885MPO 3448/4885KHK 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.